In Section A, participants will get different doses and schedules of oral ABBV-744 tablet to identify Risk-free dosing program. Extra members will be enrolled with the recognized monotherapy dosign routine. In Section B, individuals will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, participants https://bertoltv000ite3.bloggerbags.com/profile